Laddar...
Ibrutinib treatment improves T cell number and function in CLL patients
BACKGROUND. Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton’s tyrosine kinase (BTK) and IL-2–inducible T cell kinase (ITK). The relative importance of inhibiting these 2 kinases has not been examined despite its relevance to immune-based therapies. METHODS. Peripheral...
Sparad:
| I publikationen: | J Clin Invest |
|---|---|
| Huvudupphovsmän: | , , , , , , , , , , , , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
American Society for Clinical Investigation
2017
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5531425/ https://ncbi.nlm.nih.gov/pubmed/28714866 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI89756 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|